Evidence map›Paper›PMID 21731648›Full record

ArticlePloS one2011

The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination.

Subhash Thalappilly, Xiaolan Feng, Svitlana Pastyryeva, Keiko Suzuki, Daniel Muruve, Daniel Larocque, Stephane Richard, Matthias Truss, Andreas von Deimling, Karl Riabowol and 1 more

Expression of concernOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. ING2 Controls Mitochondrial RespirationFrontiers in cell and developmental biology · 2021
    Article
  12. Senescence and Apoptosis: Architects of Mammalian Development.Frontiers in cell and developmental biology · 2020
    Review
  13. Review
  14. Review
  15. INGs are potential drug targets for cancer.Journal of cancer research and clinical oncology · 2017
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Subhash ThalappillyDepartments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada.
Xiaolan Feng
Svitlana Pastyryeva
Keiko Suzuki
Daniel Muruve
Daniel Larocque
Stephane Richard
Matthias Truss
Andreas von Deimling
Karl Riabowol
Gesche Tallen
University of Calgary · CACharité - Universitätsmedizin Berlin · DEGlaxoSmithKline (Canada) · CAHeidelberg University · DEMcGill University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

The INhibitor of Growth tumor suppressors (ING1-ING5) affect aging, apoptosis, DNA repair and tumorigenesis. Plant homeodomains (PHD) of ING proteins bind histones in a methylation-sensitive manner to regulate chromatin structure. ING1 and ING2 contain a polybasic region (PBR) adjacent to their PHDs that binds stress-inducible phosphatidylinositol monophosphate (PtIn-MP) signaling lipids to activate these INGs. ING1 induces apoptosis independently of p53 but other studies suggest proapoptotic interdependence of ING1 and p53 leaving their functional relationship unclear. Here we identify a novel ubiquitin-binding domain (UBD) that overlaps with the PBR of ING1 and shows similarity to previously described UBDs involved in DNA damage responses. The ING1 UBD binds ubiquitin with high affinity (K(d)∼100 nM) and ubiquitin competes with PtIn-MPs for ING1 binding. ING1 expression stabilized wild-type, but not mutant p53 in an MDM2-independent manner and knockdown of endogenous ING1 depressed p53 levels in a transcription-independent manner. ING1 stabilized unmodified and six multimonoubiquitinated forms of wild-type p53 that were also seen upon DNA damage, but not p53 mutants lacking the six known sites of ubiquitination. We also find that ING1 physically interacts with herpesvirus-associated ubiquitin-specific protease (HAUSP), a p53 and MDM2 deubiquitinase (DUB), and knockdown of HAUSP blocks the ability of ING1 to stabilize p53. These data link lipid stress signaling to ubiquitin-mediated proteasomal degradation through the PBR/UBD of ING1 and further indicate that ING1 stabilizes p53 by inhibiting polyubiquitination of multimonoubiquitinated forms via interaction with and colocalization of the HAUSP-deubiquitinase with p53.

Indexed as

UbiquitinationCell Line, TumorHumansInhibitor of Growth Protein 1Intracellular Signaling Peptides and ProteinsModels, BiologicalMutant ProteinsNuclear ProteinsPhospholipidsPolyubiquitinProteasome Endopeptidase ComplexProtein BindingProtein Processing, Post-TranslationalProtein StabilityProtein Structure, TertiaryTumor Suppressor Protein p53ING1 protein, humanInhibitor of Growth Protein 1Intracellular Signaling Peptides and ProteinsMutant ProteinsNuclear ProteinsPhospholipidsPolyubiquitinProteasome Endopeptidase ComplexTumor Suppressor Protein p53Tumor Suppressor ProteinsUbiquitin-Specific Peptidase 7Ubiquitin ThiolesteraseUSP7 protein, human

Identifiers

PMID21731648
PMCPMC3120833
OpenAlexW2043531610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.